



NOVODIAX is dedicated to advancing tissue-based diagnostics and immunoassays. We have developed a robust system to transform an existing customer-provided therapeutic antibody to a corresponding exact-match tissue-based companion diagnostics. This therapeutic antibody conjugated polymer detection system provides exceptional specificity and sensitivity over alternative approaches. Equipped with this technology, we offer collaborations to pharmaceutical and biotech partners to streamline their therapeutic antibody development at multiple stages.

Companion Diagnostic development

NovodiAx's ihcDirect™ offer a new solution by labeling a therapeutic antibody directly with a unique super-sensitive polyHRP.

Proven case of Companion Diagnostic Development with NOVODIAX direct IHC technology platform: (Herceptin-Based IHC As a More Precise CDx for Herceptin Therapies)

A new strategy of using therapeutic antibody as CDx tool has been proven to be feasible with our technology. We look forward to collaborate with therapeutic antibody developers with the following service package.

- Conjugate your therapeutic antibody or candidate with our Super-sensitive PolyHRP.
- Optimize in situ working conditions of the conjugated antibody with positive and negative control issues.
- Your therapeutic antibody become a companion diagnostic tool, “ready to use” for all downstream development including clinical trials.

All FDA approved HER2 CDx antibodies generate large amount false positive results (see Fig 1 below). NovodiAx polyHRP-Herceptin directly detects Herceptin binding sites on cancer tissues and should be a gold standard CDx for Herceptin therapies.




Fig 1: 20-35% of breast cancer express a truncated HER2 that is detectable by all FDA approved HER2 IHC antibodies but not accessible by Herceptin.




Fig 2: NovodiAx polyHRP-Herceptin on a breast cancer tissue section.